Genetic Resistance to GLP‑1 Drugs

Researchers report that roughly 1 in 10 people carry PAM gene variants that raise circulating GLP‑1 levels but blunt the hormone’s biological effect, producing resistance to GLP‑1‑based diabetes drugs and potentially to their weight‑loss effects. The mechanism appears downstream of receptor binding and is not explained by differences in response to other diabetes medications, but the exact cellular defect remains unknown. — If common, such genetic resistance could reshape clinical prescribing, patient expectations, insurance coverage, and pharmaceutical R&D for GLP‑1 formulations or sensitizers.